Literature DB >> 11231011

Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains.

S Taniguchi1, Y Fujita, S Hayashi, A Kakita, H Takahashi, S Murayama, T C Saido, S Hisanaga, T Iwatsubo, M Hasegawa.   

Abstract

Tau in Alzheimer neurofibrillary tangles has been shown to be hyperphosphorylated and CDK5, GSK3, MAP kinase and SAP kinases are the candidate kinases for the phosphorylation of tau. Recently, it was reported that the conversion of p35, the activator of CDK5, to p25 was upregulated in Alzheimer's disease (AD) brains, and that p35 is cleaved to yield p25 by calpain. Here we show that p35 is rapidly cleaved to p25 in rat and human brains within a short postmortem delay and that the conversion of p35 to p25 is partially dependent on calpain activity. Immunoblot analysis of brains prepared from patients with AD or age-matched control individuals with a short postmortem delay revealed no specific increase in the levels of p25 in AD brains, whereas the levels of active form of calpain were increased in AD brains compared to the those in controls. These observations suggest that the conversion of p35 to p25 is a postmortem degradation event and may not be upregulated in AD brains.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11231011     DOI: 10.1016/s0014-5793(00)02431-5

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  35 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  Impact of temperature dependent sampling procedures in proteomics and peptidomics--a characterization of the liver and pancreas post mortem degradome.

Authors:  Birger Scholz; Karl Sköld; Kim Kultima; Celine Fernandez; Sofia Waldemarson; Mikhail M Savitski; Marcus Söderquist; Mats Borén; Robert Stella; Per Andrén; Roman Zubarev; Peter James
Journal:  Mol Cell Proteomics       Date:  2010-01-28       Impact factor: 5.911

3.  A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.

Authors:  Ya-Li Zheng; Niranjana D Amin; Ya-Fang Hu; Parvathi Rudrabhatla; Varsha Shukla; Jyotshnabala Kanungo; Sashi Kesavapany; Philip Grant; Wayne Albers; Harish C Pant
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

Review 4.  Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Brain Res Brain Res Rev       Date:  2005-01-08

Review 5.  Intake of ω-6 Polyunsaturated Fatty Acid-Rich Vegetable Oils and Risk of Lifestyle Diseases.

Authors:  Tetsumori Yamashima; Tsuguhito Ota; Eishiro Mizukoshi; Hiroyuki Nakamura; Yasuhiko Yamamoto; Mitsuru Kikuchi; Tatsuya Yamashita; Shuichi Kaneko
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

Review 6.  Calpain research for drug discovery: challenges and potential.

Authors:  Yasuko Ono; Takaomi C Saido; Hiroyuki Sorimachi
Journal:  Nat Rev Drug Discov       Date:  2016-11-11       Impact factor: 84.694

Review 7.  Employing new cellular therapeutic targets for Alzheimer's disease: a change for the better?

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2005-01       Impact factor: 1.990

8.  Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level.

Authors:  Amitabha Sengupta; Michal Novak; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  FEBS Lett       Date:  2006-10-05       Impact factor: 4.124

9.  Identification of small molecule inhibitors of beta-amyloid cytotoxicity through a cell-based high-throughput screening platform.

Authors:  K I Seyb; E R Schuman; J Ni; M M Huang; M L Michaelis; M A Glicksman
Journal:  J Biomol Screen       Date:  2008-09-23

Review 10.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.